Brainstorm Cell Therapeutics (BCLI) Q2 2025 Earnings Report

The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.

During the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call, the company emphasized its commitment to advancing the NurOwn platform for ALS treatment through a planned Phase IIIb trial called ENDURANCE, following FDA clearance in May. The trial's design has been agreed upon with the FDA under a Special Protocol Assessment (SPA), aiming to support a future Biologics License Application (BLA). Financially, Brainstorm reported R&D expenditures of $1.1 million for the quarter ending June 30, 2025, up from $0.9 million in 2024, and a net loss of $2.9 million compared to $2.5 million the previous year. The company is actively seeking funding to initiate the trial and regain NASDAQ compliance, following a transition to the OTCQB. Additionally, a Citizens Petition has been filed with the FDA by ALS patients and families, advocating for a de novo review of NurOwn's data, which includes promising five-year survival statistics from an expanded access program.